相关实验视频
Updated: May 21, 2025

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
对于转移性恶性植物瘤的预后因素和治疗见解
Mengjia Han1, Yunyi Zhang1, Rong Lei1
1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Guangdong, China; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Guangdong, China.
转移性恶性菌株瘤 (MMPTs) 的存活率受到无转移存活率 (MFS) 和全身化疗的影响. 患有MFS不到六个月的患者的预后较差,这强调了及时治疗的重要性.
科学领域:
- 在瘤学瘤学.
- 手术病理学手术病理学
- 医学瘤学 医学瘤学
背景情况:
- 转移性恶性植物瘤 (MMPT) 是一种罕见且具有攻击性的新生体.
- 了解MMPT的预后因素和治疗策略对于改善患者的治疗结果至关重要.
研究的目的:
- 调查影响MMPT生存的预后因素.
- 描述MMPT目前的治疗环境.
- 为了确定MMPTs患者的最佳治疗选择.
主要方法:
- 追溯多中心研究涉及43名在2009年至2023年期间接受治疗的MMPT患者.
- 主要终点:整体存活率 (OS).
- 多变量分析以确定独立的预后因素.
主要成果:
- 平均总生存时间为7.27个月;平均无转移生存时间 (MFS) 为7.27个月.
- 肺是最常见的转移部位 (81.4%).
- 化疗后转移和MFS>6个月独立地与改善的OS相关. 转移切除术并没有显著改善OS.
结论:
- 系统化疗是改善MMPT生存结果的重要因素.
- 无转移生存 (MFS) 持续时间是关键的预后指标.
- 患有MFS<6个月的患者预后较差,需要采取积极的管理策略.
更多相关视频
07:44Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
07:54Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
相关概念视频
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...